Phamacokinetics of rivaroxaban in adolescents

SummaryBackground: The direct factor Xa inhibitor rivaroxaban is approved for venous throm-boembolism (VTE) treatment in adults. However, in all phase-III trials children or adolescents have not been included. For under-aged VTE patients, current standard treatment consists of low molecular weight heparin or Vitamin K antagonists. Rivaroxaban could be an attractive alternative, however, no data on the pharmacokinetics (PK) of rivaroxaban in adolescents are currently available.Patient, methods: We report PK data for rivaroxaban derived from a girl (age:15 years), who presented three month after acute deep vein th…